百家乐怎么玩-澳门百家乐官网娱乐城网址_网上百家乐是不是真的_全讯网888 (中国)·官方网站

First dual stem cell therapy brings new hope for cardiac repair

Donna Wong

 

190910-1_research_0.jpg
Dr Ban Ki-won (middle) and his research team at CityU.

 

A research team featuring an expert from City University of Hong Kong (CityU) has developed a novel dual approach for the first time for concurrently rejuvenating both the cardiac muscle and vasculature of the heart by utilising two types of stem cells. The results give hope for a new treatment for repairing myocardial infarction (MI) heart. 

  190910-2_research_1.jpg
These are the specimens of rats’ hearts used in the research.

 

Dr Ban Ki-won, Assistant Professor of the Department of Biomedical Sciences and his research team, including researchers from Konkuk University, The Catholic University of Korea, Pohang University of Science and Technology and T&R Biofab in South Korea, have conducted the first study of two distinct stem cell effects for cardiac repair. The two major types of stem cells employed are human bone marrow derived mesenchymal stem cells (hMSCs) and cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs). The research findings have been published in Nature Communications in a paper titled “Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction”. 

“Both cardiac muscles and vasculatures are severely damaged following MI, and so the therapeutic strategies should focus on comprehensive repair of both at the same time. But the current strategies only focus on either one,” Dr Ban said. 

Dr Ban said that, with limited therapeutic options for severe MI and advanced heart failure, a heart transplant was the last resort. However, such an operation is very risky, costly and subject to limited supply of suitable donors. Therefore, stem cell-based therapy has emerged as a promising therapeutic option.

190910-3_research_4.jpg
Representative immunostaining images showing hiPSC-CM-GFP (green) and MYH6/7 gene (red) when hiPSC-CMs were injected in MI hearts.

 

In the study, the hiPSC-CMs were injected directly into the border zone of the rat's heart, while the hMSCs-loaded patch was implanted on top of the infarct area, like a bandage. The results showed that this dual approach led to a significant improvement of cardiac function and an enhancement of vessel formation on a MI heart. 

“We believe this novel dual approach can potentially provide translational and clinical benefit to the field of cardiac regeneration. Based on the same principle, the protocol may also be utilised for repairing other organs including the brain, liver and pancreas in which multiple types of stem cells co-exist,” Dr Ban added. 

The research team is working on follow-up studies in larger animal models such as pigs. The patent application for this research result has been submitted.

The first co-authors of the paper are Dr Park Soon-jung from Konkuk University School of Medicine, Dr Kim Ri-youn and PhD student Lee Sung-hun from CityU and PhD student Park Bong-woo from The Catholic University of Korea.

 

 

YOU MAY BE INTERESTED

Contact Information

Communications and Institutional Research Office

Back to top
百家乐专家赢钱打法| 百家乐有没有绝| 大发888娱乐城可靠吗| 威尼斯人娱乐城是真的吗| 百家乐官网是赌博吗| 澳门百家乐实战| 澳门赌场有老千| 百家乐官网免费改单| 太阳城百家乐注册平台| 乌兰察布市| 百家乐大路图| 现金斗地主| 百家乐羸钱法| 最好的百家乐官网论坛| 网上百家乐记牌软件| 百家乐官网怎样出千| 六合彩生肖| 百家乐号技巧| 百家乐官网不倒翁缺点| 百家乐庄闲符号记| 明升百家乐官网QQ群| 大发888娱乐场c17| E世博百家乐娱乐城| 百家乐官网庄闲必赢| 百家乐桌子北京| 百家乐官网国际娱乐网| 图木舒克市| 百家乐麻将筹码币| 赌博百家乐官网下载| 伯爵百家乐的玩法技巧和规则 | 百家乐扑克玩法| 百家乐官网视频游戏盗号| 巴登娱乐城开户| 香港百家乐玩| 风水罗盘24山| 百家乐官网最新庄闲投注法 | 百家乐官网在线赌场娱乐网规则| 百家乐与龙虎斗怎么玩| 澳门百家乐怎么玩| 澳门顶级赌场手机版| 环澳娱乐|